Skip to main content


Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

Central Nervous System API Products

Central Nervous System API Products

Central Nervous System API Products
Central Nervous System API Products

Get access to Dr. Reddy's largest CNS API portfolios to support your formulation success

Dr. Reddy’s is one of the leading generic pharmaceutical companies and CNS API suppliers in the development and manufacturing of CNS APIs used in formulations to treat indications in the central nervous system (CNS) therapy area. Our CNS API product portfolio is broad-based, including APIs in the class of atypical antipsychotics, anticholinergics, Nrf2 activators, cholinesterase inhibitors, antioxidants, and GnRH antagonists.

As CNS API manufacturer and supplier, Dr. Reddys CNS APIs for various therapeutic categories are as follows:

Bipolar Disorder/ Anti-schizophrenic
 

Bipolar Disorder/ Anti-schizophrenic - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

Anti-Parkinson’s

Anti-Parkinson’s - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

Anti-ALS

Anti-ALS - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

Multiple Sclerosis

Multiple Sclerosis - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

Anti-Alzheimer’s

Anti-Alzheimer’s - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

Major Depressive Disorder

Major Depressive Disorder - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

Pain Management

Pain Management - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

Anti-epileptic

Anti-epileptic - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

Anti-migraine

Anti-migraine - Dr. Reddy's

*Countries referred in the above graphic denotes DMF filing geographies

USPs of our CNS APIs

  • Firm PSD control to help maintain consistency of manufacturing process.
  • Sufficient capacity to meet our customer’s global leadership requirements.
  • Reliable KSM suppliers in India with timely deliveries and stringent specifications.
  • IP compliant process.
  • Well-controlled all the plausible impurities within the specified limit.
  • Commercially available starting materials.
  • Schemes of starting material evaluated.
  • Flexible business models to support registrations.
  • Adequate capacity available to supply development quantity in short lead time.
  • Free from nitrosamine impurities.
  • QBD (Quality by Design) based API development for consistent quality profile.
  • Continuous improvement in place to achieve cost and quality excellence.
  • Process safety and scalability.
  • APIs suitable for global formulation development.
  • Fully backward integration process.
  • Compliant to all pharmacopeia’s.
  • Multiple domestic sources for KSMs available.
  • Able to match a wide range of particle size requirements.
Central Nervous System (CNS) Products

Atomoxetine Hydrochloride

Therapy Area
Central Nervous System (CNS)

Benztropine Mesylate

Therapy Area
Central Nervous System (CNS)

Dimethyl Fumarate

Therapy Area
Central Nervous System (CNS)

Divalproex Sodium

Therapy Area
Central Nervous System (CNS)

Donepezil HCl

Therapy Area
Central Nervous System (CNS)

Edaravone

Therapy Area
Central Nervous System (CNS)

Escitalopram Oxalate

Therapy Area
Central Nervous System (CNS)

Eslicarbazepine Acetate

Therapy Area
Central Nervous System (CNS)

Eszopiclone

Therapy Area
Central Nervous System (CNS)

Fingolimod Hydrochloride

Therapy Area
Central Nervous System (CNS)

Levetiracetam

Therapy Area
Central Nervous System (CNS)

Lumateperone Tosylate

Therapy Area
Central Nervous System (CNS)

Lurasidone Hydrochloride

Therapy Area
Central Nervous System (CNS)

Memantine Hydrochloride

Therapy Area
Central Nervous System (CNS)

Olanzapine

Therapy Area
Central Nervous System (CNS)

Pregabalin

Therapy Area
Central Nervous System (CNS)

Quetiapine Fumarate

Therapy Area
Central Nervous System (CNS)

Risperidone

Therapy Area
Central Nervous System (CNS)

Rivastigmine Hydrogen Tartrate

Therapy Area
Central Nervous System (CNS)

Ropinirole Hydrochloride

Therapy Area
Central Nervous System (CNS)

Siponimod

Therapy Area
Central Nervous System (CNS)

Tizanidine Hydrochloride

Therapy Area
Central Nervous System (CNS)

Vilazodone Hydrochloride

Therapy Area
Central Nervous System (CNS)

Ziprasidone Hydrochloride

Therapy Area
Central Nervous System (CNS)

Zuranolone

Therapy Area
Central Nervous System (CNS)

Explore other Therapeutic categories.

FAQs

Our CNS API product portfolio is broad-based, including APIs in the class of atypical antipsychotics, anticholinergics, Nrf2 activators, cholinesterase inhibitors, antioxidants, and GnRH antagonists.

They can act either as neurotransmitter agonists, such as the opioids, which mimic the action of enkephalin, or they can block receptor function. Receptor antagonism is a common mechanism of action for CNS drugs.

The global central nervous system therapeutic market was valued at 116.2 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 7.4% from 2021 to 2028. Advancements in diagnostics and therapeutics of CNS diseases are expected to increase the treatment rate globally.

Used to treat insomnia (trouble sleeping), anxiety, panic attacks, and seizures. They may also be used to relieve anxiety and tension before surgery. Examples of CNS depressants are benzodiazepines, barbiturates, and certain sleep medicines.

Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.

X
Checked out our

API Linkedin
page yet?

Follow this page to explore how our offerings can accelerate your formulation success

Click here to visit